Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This study evaluated adverse events (AEs), study discontinuation due to AEs, and pharmacodynamics of MK-8266 in male participants with mild to moderate hypertension.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.